Objective：To investigate the clinical efficacy of short-term intensive antiplatelet treatment of ticagrelor for patients with low response to clopidogrel after percutaneous coronary intervention（PCI）. Methods：A total of 100 cases who underwent PCI and were confirmed with low response to clopidogrel by light transmittance aggregation（LTA）were consecutively recruited and equally randomized into Clopidogrel（n=50）and Ticagrelor（n=50）groups. In Clopidogrel group，patients maintained clopidogrel 75 mg，gd in combination with aspirin 100 mg，gd；while in Ticagrelor group，patients were treated with ticagrelor 90 mg twice daily for 1 month，then switching to clopidogrel 75 mg，gd in combination with aspirin 100 mg，gd. The light transmission aggregations were determined for all patients 1 month after randomization；all participants were followed up and the adverse cardiovascular events were recorded for 6 months. Results：There were no significant differences between the two groups regarding both the adenosine diphosphate-induced platelet aggregation（PLADP）and the arachidonic acid-induced platelet aggregation（PLAA）prior to randomization（P > 0.05）. At 1 month after randomization，PLADP in the Ticagrelor group was significantly lower than that in the Clopidogrel group［（21.27 ± 12.81）% vs.（48.72 ± 10.92）%］（P < 0.01），while PLAA showed no significant difference between the two groups. The incidence of cardiogenic rehospitalization was significantly lower（6% vs. 20%，P < 0.05），although minimal bleeding was significantly higher（24% vs. 8%，P < 0.05）in the Ticagrelor group compared with that in the Clopidogrel group. Conclusion：The antiplatelet effect of ticagrelor is significantly more potent than that of clopidogrel，and 1-month intensive treatment of ticagrelor may reduce the cardiogenic rehospitalization in patients with CLR after PCI.